Krystal Biotech, Inc. — Director's Dealing 2021

Jun 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2021-05-31

Reporting Person: ORTH ANDREW C. (Chief Commercial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-31	Stock Option (Right to Buy)	$65.24	A	205000	Acquired	2031-05-31	Common Stock (205000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	100	Direct

Footnotes

F1: The option vests in four equal annual installments beginning on May 3, 2022.